A Phase IV, Multicentre Randomized Prospective Open Label Study to Evaluate Whether Switching From Current cART to Triumeq in Addition to Adherence Support Will Enhance Virologic Control and Adherence in Vulnerable Populations Relative to Adherence Support Alone
Phase of Trial: Phase IV
Latest Information Update: 29 Sep 2016
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 20 Sep 2016 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 20 Sep 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
- 21 Mar 2016 Planned End Date changed from 1 Mar 2018 to 1 Jan 2018, according to ClinicalTrials.gov record.